Boothwyn, PA, United States of America

Rupalie Meegalla


Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2007

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Inventor Spotlight: Rupalie Meegalla

Introduction

Rupalie Meegalla, an innovative inventor located in Boothwyn, Pennsylvania, has made significant contributions to the field of biotechnology. His research and development efforts led to the creation of a unique patent that holds promise for various medical applications, particularly in the treatment and prevention of obesity.

Latest Patents

Rupalie Meegalla holds one notable patent titled "Polynucleotide encoding a novel acyl coenzyme A, monoacylglycerol acyltransferase-3 (MGAT3), and uses thereof." This groundbreaking invention features polynucleotides that encode MGAT3 polypeptides along with fragments and homologues. The patent outlines the methods for producing these polypeptides and discusses their potential use in diagnosing and treating disorders such as obesity. Moreover, the patent covers innovative diagnostic and therapeutic applications, as well as screening methods to identify agonists and antagonists of the MGAT3 polypeptides.

Career Highlights

Rupalie has been associated with Bristol-Myers Squibb Company, a renowned pharmaceutical firm that fosters research and development in a variety of therapeutic areas. His role within this esteemed company has allowed him to refine his inventions and contribute to pioneering projects in biotechnology.

Collaborations

Throughout his career, Rupalie Meegalla has collaborated with notable colleagues, including John N. Feder and Thomas C. Nelson. These partnerships have enabled him to engage in interdisciplinary work, further enhancing the impact of his inventions on the scientific community.

Conclusion

Rupalie Meegalla is a distinguished inventor whose work has paved the way for advancements in biotechnology and therapeutic treatments. His patent on MGAT3 polypeptides signifies a noteworthy achievement in the ongoing battle against obesity and related disorders. As innovations continue to unfold in this field, Meegalla's contributions stand out for their potential to improve public health and medical outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…